ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Journal of Molecular Biology
Volume 365, Issue 5, 2 February 2007, Pages 1533-1544
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (1614 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.jmb.2006.10.088    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2006 Elsevier Ltd All rights reserved.

Structural Basis of Enhanced Binding of Extended and Helically Constrained Peptide Epitopes of the Broadly Neutralizing HIV-1 Antibody 4E10

Rosa M.F. Cardoso1, Florence M. Brunel2, Sharon Ferguson1, Michael Zwick3, Dennis R. Burton1, 3, Philip E. Dawson2, 4 and Ian A. Wilson1, 4, Corresponding Author Contact Information, E-mail The Corresponding Author

1Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA 2Department of Chemistry and Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA 3Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA 4Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

Received 31 July 2006; 
revised 24 October 2006. 
Edited by R. Huber. 
Available online 10 November 2006.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Potent, broadly HIV-1 neutralizing antibodies (nAbs) may be invaluable for the design of an AIDS vaccine. 4E10 is the broadest HIV-1 nAb known to date and recognizes a contiguous and highly conserved helical epitope in the membrane-proximal region of gp41. The 4E10 epitope is thus an excellent target for vaccine design as it is also highly amenable to peptide engineering to enhance its helical character. To investigate the structural effect of both increasing the peptide length and of introducing helix-promoting constraints in the 4E10 epitope, we have determined crystal structures of Fab 4E10 bound to an optimized peptide epitope (NWFDITNWLWYIKKKK-NH2), an Aib-constrained peptide epitope (NWFDITNAibLWRR-NH2), and a thioether-linked peptide (NWFCITOWLWKKKK-NH2) to resolutions of 1.7 Å, 2.1 Å, and 2.2 Å, respectively. The thioether-linked peptide is the first reported structure of a cyclic tethered helical peptide bound to an antibody. The introduced helix constraints limit the conformational flexibility of the peptides without affecting interactions with 4E10. The substantial increase in affinity (10 nM versus 104 nM of the IC50 of the original KGND peptide template) is largely realized by 4E10 interaction with an additional helical turn at the peptide C terminus that includes Leu679 and Trp680. Thus, the core 4E10 epitope was extended and modified to a WFX(I/L)(T/S)XX(L/I)W motif, where X does not play a major role in 4E10 binding and can be used to introduce helical-promoting constraints in the peptide epitope.

Keywords: 4E10; gp41; crystal structure; antibody; AIDS vaccine

Abbreviations: HIV-1, human immunodeficiency virus type 1; CDR, complementarity-determining region; Aib, α-amino isobutyric acid

Article Outline

Introduction
Results
Structure determination and refinement
Structure of Fab 4E10
Structure of the peptide epitope
The combining site
Expansion of the core epitope
Discussion
Material and Methods
Peptide synthesis and purification
Preparation of complexes, crystallization and data collection
Structure determination and refinement
Structural analysis
Binding affinity by ELISA
Binding affinity by surface plasmon resonance
Protein Data Bank accession codes
Acknowledgements
References




Journal of Molecular Biology
Volume 365, Issue 5, 2 February 2007, Pages 1533-1544
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.